Articles tagged with Cancer Patients
A recent study found that a substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer through increased screening via computed tomography (CT) and follow-up scans. This approach can lead to surgical interventions, which can often be curative for precancerous nodules.
Researchers are part of a five-year global study examining the behavioral and long-term health impacts of different regulatory approaches to e-cigarettes and other new nicotine products among youth and adults in seven countries. The study aims to inform US public policy based on evidence, maximizing population health.
A new study warns that Omicron could lead to 100,273 fewer elective operations performed over the three winter months due to increased hospital admissions and COVID-19 patients. The model used NHS England data from September 2020 to July 2021 to project elective surgery activity based on the number of COVID-19 patients in hospital.
A recent study has identified a new mechanism by which oral cancer cells acquire radioresistance through the transfer of microRNA, specifically miR-503-3p. This discovery brings hope for the development of new treatments for radiation-resistant oral cancer.
A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.
The KEYNOTE-811 trial demonstrates a significant improvement in objective response rate (74.4%) and tumor size reduction compared to trastuzumab and chemotherapy. The combination of pembrolizumab, trastuzumab, and chemotherapy markedly reduces tumor size and induces complete responses in some patients.
Researchers have discovered that a common class of targeted therapies can help more colorectal cancer patients than previously thought. By analyzing cell studies and computer modeling, the team identified 10 distinct RAS mutations that do not preclude the use of EGFR inhibitors, which are already approved for other uses.
A Phase 2 clinical trial showed sotorasib can shrink tumors and achieve disease control in heavily pretreated patients with advanced colorectal cancer. The study results exceeded the historic benefits linked to approved therapies, offering new hope for a population with limited treatment options.
A study found that rural women are less likely to get screened for colorectal cancer compared to urban counterparts, despite similar breast cancer screening rates. The disparity may be attributed to limited access to testing and financial constraints, highlighting the need for targeted public health interventions.
Researchers have discovered that NOR-1 protein can provide broad protection against heart damage following cancer treatment. Administering the protein directly may reduce heart risk, at least in laboratory tests.
A new treatment combination of dasatinib, blinatumomab, and prednisone has shown promise in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. The trial achieved a three-year DFS rate of 80 percent and an overall survival rate of 85 percent for enrolled patients.
Surgeons at Henry Ford Health performed the world's first precision prostatectomy through the bladder using a single port robotic surgical system. The procedure preserves a portion of the prostate capsule, improving functional outcomes such as erectile function and urinary control.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
A team developed statistical models to predict the risk of early death in patients with non-intensive AML therapy. The models incorporated various health measures and quality-of-life scores, showing modest success in predicting outcomes.
A new NRG Oncology clinical trial found that bupropion did not improve sexual desire in female cancer survivors. The trial evaluated the effects of extended-release bupropion on postmenopausal women with low baseline sexual desire scores.
Research reveals tamoxifen boosts PI3K signaling, potentially increasing uterine cancer risk in breast cancer patients. Preclinical studies show PI3K inhibitor alpelisib mitigates this effect.
Researchers discovered that the SET2,3 index provides complementary prognostic information about breast cancer outcomes, particularly for patients with hormone receptor-positive breast cancer. The study suggests that using both clinical and molecular information from a patient's tumor can guide treatment decision-making.
Investigators at Weill Cornell Medicine identified significant age-related differences in tumor characteristics across various cancers, suggesting potential for personalized treatment approaches. They found that tumors from younger patients showed advanced signs of aging and more mutations associated with aggressive disease.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
A new protein variant called CLIP-170S allows cancer cells to dodge chemotherapy drugs, rendering them ineffective. Researchers discovered this variant in more than 60% of patients with gastric cancer and are exploring a combination therapy involving imatinib to overcome resistance.
A University of Gothenburg study found that bariatric surgery lowers cancer risk by 60% in obese patients with type 2 diabetes, particularly those achieving and maintaining normal glucose control. The research highlights the importance of glucose control in preventing cancer in this high-risk population.
Researchers at Case Western Reserve University are developing an AI tool to analyze medical images and determine which rectal cancer patients require surgery. By using radiomics and machine learning techniques, the team hopes to identify patients who can avoid invasive surgery and opt for chemotherapy or radiation therapy instead.
A new study found that bowel cancer patients are at high risk of clinical levels of depression, with over a third experiencing symptoms up to five years after surgery. The study identified risk factors such as pre-existing depression and anxiety, low social support, and poor health.
A study found that COVID-19 vaccination significantly lowers the risk of SARS-CoV-2 infection among patients with cancer. The vaccinated group had a lower incidence of COVID-19 compared to those who did not receive the vaccine.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
A new diagnostic tool for breast cancer uses a low-voltage electrical current to detect changes in lymphatic interstitial fluid, showing 70% effectiveness in predicting cancer presence. The device can be used repeatedly on women of any age, providing an additional diagnostic option for younger patients and those with dense breast tissue.
Researchers analyzed data from 2016 to 2020 and found no significant difference in new cancer diagnoses among Canadian children during the pandemic. The study suggests that cancer diagnosis rates were not delayed, unlike previous reports suggesting a decline.
The study evaluated outcomes of minimally invasive esophagectomy compared to open esophagectomy in 6000 ESCC patients over 10 years. MIE was found to be an effective treatment option even for large tumors, expanding its indicated population.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
Research found that proton pump inhibitors (PPIs) may reduce the effectiveness of immune checkpoint inhibitor drugs in patients with non-small-cell lung cancer. PPI use was associated with worse survival rates and a significant decrease in the benefit of immune therapy treatment.
Researchers at Karolinska Institutet found that certain bacteria from the digestive system can cause damage to pancreatic cells, increasing the risk of malignant tumours. The study suggests that antibiotics could prevent this damage, offering a potential prophylactic intervention.
A registry-based study of 2,600 patients in six European countries reveals a significant increase in COVID-19 mortality among cancer patients during the pandemic. The study suggests that cancer patients are at higher risk of severe illness and death from COVID-19 due to underlying health conditions.
Researchers found that second-generation antihistamines block histamine binding to HRH1, improving cytotoxic T cell activation and reducing resistance to immunotherapy. High plasma histamine levels in patients were correlated with worse responses to anti-PD-1 immunotherapy.
Researchers found that antihistamines improve responses to immune checkpoint inhibitors in cancer patients, particularly those with pre-existing allergies or high plasma histamine levels. The study suggests targeting the histamine receptor HRH1 may be a useful treatment approach.
Early antiretroviral therapy reduces skin and mucosal cancers in HIV patients by preserving tissue-resident memory T cells. Prompt treatment also improves the immune response, reducing the risk of HPV-associated cancers.
Despite increases in inclusion, certain groups remain under-represented in cancer clinical trials. Black and Hispanic patients showed improved participation, while women and older adults continued to be under-represented.
Researchers from the University of Copenhagen have discovered a natural substance, a flavonoid, that can inhibit cancer cells' ability to defend themselves against chemotherapy by targeting efflux pumps. This could lead to more effective treatment and potentially even combat antibiotic resistance.
Researchers found that higher lymphoma volume at diagnosis was associated with increased risk of recurrence. This could lead to improved patient outcomes by selecting the most appropriate treatment. The study also explored PET-based measures of initial disease burden, which may help predict patients' risk of recurrence.
Researchers at the University of Helsinki and Aalto University have developed a gel-grown mini-breast cancer model that can effectively treat hormone-dependent breast cancers. The discovery opens new avenues for hormonal therapies, individual drug responses, and drug resistance mechanisms.
A new AI model has been developed to classify colorectal polyps, demonstrating accuracy and sensitivity at a level comparable to practicing pathologists. The model was tested in a clinical trial involving 15 pathologists, showing significant improvements in accuracy compared to traditional methods.
A study of 16,000 patients with new cancer diagnoses found that those from higher socioeconomic backgrounds were more likely to use telemedicine in the months following their diagnosis. Higher socioeconomic groups also showed increased utilization of telemedicine services within 30 days of diagnosis during the COVID-19 pandemic.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers developed a novel model to identify specific genes and genetic alterations in multiple myeloma, stratifying the cancer's severity via DNA and RNA sequencing. This model revealed diverse subtypes and high-risk patients beyond current classifications.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
A survey of parents and caregivers of children with cancer revealed that nearly a third expressed hesitation to vaccinate against COVID-19. Factors associated with willingness or hesitancy included confidence in science, medicine, and vaccination, as well as concerns about infection risks and vaccine safety.
A Mount Sinai study reveals that young adult cancer patients exhibit distinct genetic hallmarks and immune system responses compared to their older counterparts. These findings suggest personalized treatment approaches for young adults with various types of cancers.
A new study by Montefiore Einstein Cancer Center investigators found that a COVID-19 booster shot helps most cancer patients with no immune response after two-dose vaccination, significantly increasing antibody levels. The study also shows that all cancer patients benefit from vaccination, particularly those with blood cancer.
A study found that lung cancer screening rates increased significantly among high-risk males who gained access to Medicare, with a 16% jump in screenings reported. The rise is attributed to the reduced out-of-pocket costs and greater access to care for these individuals, many of whom were previously uninsured.
A researcher at MUSC's Hollings Cancer Center is developing 'living drugs' by precision-engineering CAR Tregs to treat autoimmune diseases. The CAR Tregs can delay or reduce damaging inflammation, offering a potential solution for conditions like Type 1 diabetes.
Women with breast cancer are at a higher risk of developing atrial fibrillation and dying from heart-related issues within the first year. The condition was more common in women who did not receive surgery or radiation as their initial treatment.
This study found high expression of Myosin 1g in pediatric acute lymphoblastic leukemia, suggesting its potential role in disease pathogenesis, particularly in high-risk patients. The research also showed that Myo1g may serve as a biomarker for identifying patients with an increased risk of relapse.
A large group of patients with diverse cancer types received two doses of SARS-CoV-2 vaccines or one dose of the Johnson and Johnson vaccine, showing modestly impaired immune responses. Booster vaccine doses enhanced immunity in most patients.
Researchers have developed a simple, postal urine test that can detect signs of urothelial cancer in Lynch Syndrome (LS) patients, who are at high risk of developing tumors. The test uses cell-free DNA shed into the urine to identify DNA from tumor cells with characteristic microsatellite instability.
Researchers developed a mathematical model that can predict the effectiveness of immunotherapy treatment for individual patients based on standard clinical measures. The model showed high sensitivity in predicting treatment response within two months, with minimal false-negative results.
A Johns Hopkins-led study found that leptin cancels out the effects of Tamoxifen, making it ineffective for obese patients with breast cancer. Researchers suggest that interventions targeting leptin or Med1 may improve Tamoxifen's success in this group.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A phase 2 clinical trial shows durvalumab immunotherapy combined with standard chemotherapy significantly improved overall survival for patients with previously untreated malignant pleural mesothlioma. The study's findings provide insights into patient selection methods for this novel chemo-immunotherapy regimen.
A study found that patients from ethnic minority groups had lower mortality rates compared to white British people. Patients from Indian, Pakistani, and other ethnic backgrounds were 16-30% less likely to die within one year of diagnosis.
Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.